Because indirect PINK1 activation can be triggered by the uncoupling of the mitochondria,9 we focused our search for small‐molecule PINK1 activators on niclosamide (Figure 1 A); an anthelminthic drug previously reported for its potential in treating myeloma through the uncoupling of oxidative phosphorylation in the mitochondria.10 Given that niclosamide has been used for a long time as a safe anthelminthic drug11 and studied in vivo with no apparent severe side effects,12 we were encouraged to explore the activation of PINK1 by this clinical agent. Here, PINK1 is linked to plasma cell myeloma.